DFDA

ARNI (Sacubitril/Valsartan)

Treatment for Dilated Cardiomyopathy

Typical Dosage: Sacubitril/Valsartan 24/26mg BID up to 97/103mg BID

Effectiveness
90%
Safety Score
65%
Clinical Trials
1
Participants
25K

Comparative Safety Scale(Higher is safer)

Cyanide☠ī¸
Meth💀
CigarettesđŸšŦ
Chemoâ˜ĸī¸
AlcoholđŸē
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
65
DangerousModerateSafe
Treatment Details
Dosage Range
Sacubitril/Valsartan 24/26mg BID up to 97/103mg BID
Time to Effect
2-8 weeks
Treatment Duration
lifetime
Evidence Quality
HIGH
Number Needed to Treat (NNT)
21(Treat 21 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
25(Treat 25 patients to see 1 additional serious adverse event)
Confidence Score
95%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$6,200
Monitoring:$700
Side Effect Mgmt:$200
Total Annual:$7,100
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOOD
ICER
$50,000/QALY
QALYs Gained
0.5
Outcome-Based Costs
Cost per Responder
$9,467
Cost per Remission
$142,000
Comparison vs ACE Inhibitor (e.g., Enalapril)
Cost Difference
+$6,100/year
More expensive
QALY Difference
+0.50 QALYs
Better outcomes
Dominance
No dominance
ARNI (Sacubitril/Valsartan) Outcomes

for Dilated Cardiomyopathy

Efficacy Outcomes
Overall Effectiveness
+90%
Response Rate
+75%
Remission Rate
+5%
Common Side Effects
Hypotension
+18%
Hyperkalemia
+8%
Cough
+7%
Angioedema
+0.5%

Sources:

nih.gov
nih.gov
nih.gov

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

Active Clinical Trials
1 active trial recruiting for ARNI (Sacubitril/Valsartan) in Dilated Cardiomyopathy

Comparative Efficacy of ARNI Versus ACE Inhibitor Therapy in Egyptian Children With Dilated Cardiomyopathy

NCT07197372NOT YET RECRUITING
View Study
70 participants
OBSERVATIONAL
Started: May 30, 2026